Morning Overview on MSN

A VA study of 588,000 patients ties GLP-1 drugs to a 35% higher risk of vision loss

Millions of Americans taking GLP-1 receptor agonists for type 2 diabetes or weight loss now face a new safety question. A ...
Morning Overview on MSN

People on Ozempic-style drugs quietly started moving less, a Fitbit study found

Adults who started taking GLP-1 receptor agonist drugs such as semaglutide logged fewer daily steps and less time exercising ...